Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (VKTX) is a clinical-stage biopharmaceutical company pioneering receptor-targeted therapies for metabolic and endocrine disorders. This page serves as the definitive source for all official updates and analysis-worthy developments related to the company’s innovative pipeline.
Investors and industry observers will find timely, verified information spanning clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes press releases on key programs like the thyroid receptor agonist VK2809 for NASH, dual GLP-1/GIP agonist VK2735 for obesity, and rare disease candidate VK0214 – all developed through Viking’s receptor-specific therapeutic approach.
Content is organized to highlight material events including Phase 1-3 trial results, FDA communications, patent developments, and peer-reviewed research publications. Each update is contextualized within Viking’s broader mission to address unmet needs in metabolic health through precision pharmacology.
For consistent monitoring of Viking’s advancements in liver disease and endocrine disorder treatments, bookmark this page and revisit for authoritative reporting on trial data disclosures and corporate announcements. All content adheres to strict journalistic standards for accuracy and regulatory compliance.
Viking Therapeutics (NASDAQ: VKTX), a biopharmaceutical company focused on therapies for metabolic disorders, will participate in two upcoming investor conferences. On June 17, 2021, Viking will engage in 1-on-1 meetings at the SVB Leerink CybeRx Series: Liver Disease Day. Following that, from June 21-23, 2021, they will host a panel discussion on June 23 at 12:00 p.m. Eastern during the Raymond James Human Health Innovations Conference. Viking is also developing innovative drugs like VK2809 for NASH and VK0214 for X-ALD, aiming to enhance patient outcomes.
Viking Therapeutics, Inc. (NASDAQ: VKTX) reported its financial results for Q1 2021, revealing a net loss of $14.0 million, or $0.19 per share, compared to a $9.7 million loss in Q1 2020. The company continues its Phase 2b VOYAGE trial for VK2809 in NASH, with enrollment expected to complete in H2 2021. The cash balance stands at approximately $242 million, providing a strong runway for its clinical programs. Key advancements include ongoing trials for VK0214, aimed at treating X-ALD, with a Phase 1b study anticipated this summer.
Viking Therapeutics (NASDAQ: VKTX) announces it will release its Q1 2021 financial results after market close on April 28, 2021. A conference call to discuss these results and corporate updates will commence at 4:30 p.m. ET on the same day. Interested parties can participate via phone or listen online through the company's webcast. Viking is focused on developing therapies for metabolic and endocrine disorders, with key projects including VK2809 for NASH and VK0214 for X-ALD.
Viking Therapeutics announces that CEO Brian Lian, Ph.D., will present at the 20th Annual Needham Virtual Healthcare Conference from April 12-15, 2021. His presentation is scheduled for April 14 from 3:45 – 4:25 p.m. Eastern. The company focuses on developing innovative therapies for metabolic and endocrine disorders, including VK2809, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH). VK0214 is also in a Phase 1 trial for X-linked adrenoleukodystrophy (X-ALD). For more information, visit vikingtherapeutics.com.
Viking Therapeutics (NASDAQ: VKTX) has announced its participation in three upcoming investor conferences. The first is the HC Wainwright Global Life Science Conference on March 9-10, 2021, where a corporate presentation will be available online. This is followed by the 33rd Annual Roth Conference on March 15-17 and the Oppenheimer's 31st Annual Healthcare Conference on March 16-18, with presentations and meetings scheduled. The company focuses on therapies for metabolic disorders, including its drugs VK2809 and VK0214, currently in clinical trials.
Viking Therapeutics (NASDAQ: VKTX) reported its fourth quarter and full-year 2020 financial results, revealing a net loss of $10.9 million for Q4, up from $7.5 million in Q4 2019. The total net loss for 2020 was $39.5 million, compared to $25.8 million in 2019. R&D expenses surged to $31.9 million, driven by clinical trial costs. The company maintains a strong balance sheet with $248.4 million in cash. Viking's ongoing VOYAGE trial for VK2809 and progress in the VK0214 program highlight its focus on metabolic disorders.
Viking Therapeutics (NASDAQ: VKTX) will report its financial results for Q4 and year-end 2020 after market close on February 17, 2021. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss the results and corporate updates. Investors can participate by dialing (844) 850-0543 or (412) 317-5199, and a telephone replay will be available until February 24, 2021. Viking is focused on metabolic and endocrine disorder therapies, with ongoing clinical programs for VK2809 and VK0214.
On January 6, 2021, Viking Therapeutics (NASDAQ: VKTX) announced the promotion of Greg Zante to Chief Financial Officer and Marianne Mancini to Chief Operating Officer. Zante brings nearly 25 years of experience in financial management and previously served as Senior Vice President of Finance at Viking. Mancini has over 30 years of experience, focusing on clinical trials, and was previously Senior Vice President of Clinical Operations. These promotions reflect their significant contributions to the company, particularly in advancing therapies for metabolic disorders including non-alcoholic steatohepatitis (NASH).
Viking Therapeutics, Inc. (NASDAQ: VKTX) announced its CEO, Brian Lian, Ph.D., will present at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The presentation will be available online starting on January 11. Viking Therapeutics specializes in developing innovative therapies for metabolic and endocrine disorders. Key programs include VK2809, targeting non-alcoholic steatohepatitis (NASH) and fibrosis, and VK0214, aimed at X-linked adrenoleukodystrophy (X-ALD), indicating strong potential in the biopharmaceutical landscape.
Viking Therapeutics (NASDAQ: VKTX) is set to present at the Stifel Healthcare Conference 2020, with CEO Brian Lian, Ph.D., delivering insights on the company's innovative therapies for metabolic and endocrine disorders. The virtual event will occur from November 16-18, 2020, with Viking's presentation scheduled for 11:40 a.m. PST on November 17, 2020. Investors can access the live webcast on Viking's website, where a replay will also be available post-conference. Viking is advancing its clinical programs, which include VK2809 and VK0214, targeting significant health issues.
FAQ
What is the current stock price of Viking Therapeutics (VKTX)?
What is the market cap of Viking Therapeutics (VKTX)?
